The UK’s National Institute for Health and Care Excellence (NICE) has recommended Janssen’s Ustekinumab for the treatment of patients with moderate-to-severe Crohn’s disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Also known as Stelara, ustekinumab is recommended for routine National Health Service (NHS) use as an option for treating the disease in adult patients who have had little or no response, or intolerance to existing therapies.

Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the digestive system, with symptoms including stomach cramps, diarrhoea, and fatigue.

NICE health technology evaluation centre director professor Carole Longson said: “We are delighted to be able to recommend ustekinumab for routine NHS use.

See Also:

“Crohn’s disease can have a debilitating impact on a person’s quality of life, from self-esteem through to experiencing regular relapses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Ustekinumab provides a convenient and viable option for patients with Crohn’s. It is a new way of treating the disease compared to conventional treatment, and can be used where other options have already been tried and stopped working.”

Already recommended by NICE for psoriasis and psoriatic arthritis treatments, ustekinumab is a new human monoclonal antibody treatment that binds to specific proteins on cells known as IL-21 and IL-23.

"Ustekinumab provides a convenient and viable option for patients with Crohn’s."

This helps stop the production of cytokines that cause the inflammatory response inside the human body.

Crohn’s disease follows an unpredictable pattern of remission and relapse, thereby significantly affecting the patient’s everyday life.

Evidence revealed that ustekinumab enhances the quality of life and is well tolerated amongst patients with the disease.

If NICE recommends ustekinumab 'as an option' in final guidance, the NHS will have to ensure that the treatment is available within three months of its date of publication.

Image: Stomach cramps in Crohn’s disease. Photo: courtesy of National Institute for Health and Care Excellence.